Related by context. All words. (Click for frequent words.) 64 evaluating picoplatin 62 unresectable locally advanced 62 oral ridaforolimus 61 immunotherapeutic agent 60 evaluating T DM1 59 ongoing Phase 1b 59 metastatic CRC 59 evaluating ispinesib 59 soft tissue sarcoma 58 R sorafenib tablets 58 3 registrational trial 58 Phase #b/#a clinical 58 metastatic castrate resistant 58 trastuzumab DM1 T DM1 57 Genasense ® 57 OAB overactive bladder 57 systemic anaplastic large 57 modified glutathione analog 57 PDX pralatrexate 57 alvespimycin 57 Empatic ™ 57 Troxatyl 57 phase IIb clinical 57 Cloretazine ® 57 metastatic carcinoma 56 including eniluracil ADH 56 Fibrin Pad 56 MAGE A3 ASCI 56 2 methoxyestradiol 56 Phase Ib IIa 56 lintuzumab SGN 56 metastatic renal cell 56 stage antibody MT# 56 TELINTRA R 56 Amrubicin 56 TBC# 56 metastatic GIST 56 Contrave# 56 thrombin component 56 refractory chronic lymphocytic 56 5 fluorouracil leucovorin 56 VEGFR2 inhibitor 56 metastatic HRPC 56 delivers fluocinolone acetonide FA 56 EGFr humanized monoclonal antibody 56 CoreValve System 56 EGFR expressing metastatic colorectal 56 nilotinib Tasigna ® 55 candidate AQ4N 55 metastatic CRPC 55 refractory metastatic colorectal cancer 55 EGFR expressing mCRC 55 PI3K/Akt pathway inhibitor 55 XL# anticancer compounds 55 virus HCV protease inhibitor 55 assessing T DM1 55 generation Hsp# inhibitor 55 recurrent metastatic 55 sNDA submission 55 candidate AP# 55 LymphoStat B belimumab 55 Intravenous palifosfamide 55 ospemifene 55 Allovectin 7 55 leading oral taxane 55 approved incretin mimetic 55 advanced unresectable 55 tumors GIST 55 LymphoStat B TM 54 docetaxel Taxotere R 54 hormone refractory prostate cancer 54 advanced nonsquamous NSCLC 54 Panzem R 54 refractory PTCL 54 L BLP# 54 treat refractory angina 54 Cleviprex TM clevidipine 54 cell carcinoma RCC 54 adjuvant GIST 54 SUCCEED trial 54 anthracycline taxane 54 CRMD# 54 ELACYT 54 metastatic castration resistant 54 catheter occlusion 54 Anturol ® 54 cetuximab Erbitux 54 Genasense ® oblimersen 54 HGS ETR1 mapatumumab 54 VELCADE melphalan 54 BRIM3 54 interferon gamma 1b 54 retinal vein occlusion induced 54 KRYSTEXXA TM pegloticase 54 candidate XP# 54 Personalized Immunotherapy 54 investigational antiplatelet agent 54 refractory Hodgkin lymphoma 54 plus prednisone 54 ENRICH trial 54 hypoxia selective 54 metastatic colorectal carcinoma 54 PEGINTRON REBETOL combination 54 Besivance 54 Zemiva TM 54 MOZOBIL 54 RANK Ligand inhibitor 54 PROVENGE ® 54 generation DACH Platinum 54 BioGlue ® 54 TOCOSOL Camptothecin 54 Phase IIb clinical 53 oral nucleoside analogue 53 unique alkylating agent 53 Genasense R 53 Epothilone D 53 data management Clintrial 53 metastatic colorectal cancer 53 Phase 2b clinical 53 AAG geldanamycin analog 53 Argatroban 53 Vicinium TM 53 pediatric pontine glioma 53 Iluvien ® 53 glufosfamide 53 OncoVEX GM CSF 53 sapacitabine CYC# 53 markets Testim ® 53 multiple myeloma MM 53 generation geldanamycin analog 53 R sipuleucel T 53 BRINAVESS 53 progressive metastatic prostate 53 following fluoropyrimidine oxaliplatin 53 tenofovir emtricitabine 53 evaluating RH1 targeted 53 evaluating Actimmune 53 Cancer AACR NCI 53 dasatinib Sprycel ® 53 oral picoplatin 53 relapsed refractory multiple myeloma 53 radiation enteritis 53 CVP chemotherapy 53 opioid induced bowel dysfunction 53 Telatinib 53 Aurexis 53 octreotide implant 53 Rhucin ® recombinant 53 cisplatin vinorelbine 53 RH1 targeted chemotherapeutic agent 53 orally administered inhibitor 53 cangrelor 53 Ixempra 53 IV APAP 53 Entereg R 53 FOLFOX6 chemotherapy regimen 53 highly purified pasteurized 53 alvimopan 53 pharmacogenomic translational research 53 unresectable 53 refractory multiple myeloma 53 Zelrix 53 dimebon latrepirdine 53 Luveris R Ovidrel R 53 acyclovir Lauriad R 53 recurrent metastatic ovarian cancer 53 recurrent glioblastoma multiforme 53 mertansine 53 cerebral oximeter available 53 FOLOTYN ® 53 mRCC 53 BEMA TM Buprenorphine 53 opioid induced constipation OIC 53 treat atrial flutter 53 alkylating agent 53 dacarbazine 53 initiate Phase 1b 53 product AMD# 53 Soliris eculizumab 53 PrevOnco ™ 53 DCVax ® Brain 53 next generation URAT1 53 lorvotuzumab mertansine 53 pralatrexate 53 evaluating intravenous picoplatin 53 non porcine pancreatic 53 Lucanix R 53 Adis Medunjanin awaits 53 plus dacarbazine 52 non squamous 52 6 sulfatase 52 acute GI GVHD 52 advanced biocompatible coatings 52 HGS ETR1 52 TRIOLEX HE# APOPTONE HE# 52 T Pred 52 product candidate Lpathomab 52 GVAX ® 52 PANVAC VF 52 plus prednisone prednisolone 52 development peramivir neuraminidase 52 CEL SCI Phase III 52 novel VDA molecule 52 ThermoDox R 52 carboplatin paclitaxel 52 hypoxia activated prodrug 52 rALLy clinical trial 52 XL# SAR# 52 docetaxel Injection Concentrate 52 BRIM2 52 candidate REP# 52 oxybutynin ATD TM 52 FOLFOX chemotherapy 52 candidate brentuximab vedotin 52 metaglidasen 52 ANCHOR trial 52 metastatic hormone refractory 52 palifosfamide Zymafos TM 52 Cloretazine R VNP#M 52 whose tumors overexpress 52 EMD # 52 novel histone deacetylase 52 Panzem R NCD 52 phase IIb study 52 FavId 52 SinuNase TM 52 plus gemcitabine 52 bevacizumab Avastin ® 52 GVAX R 52 omacetaxine mepesuccinate 52 dopamine receptor agonist 52 metastatic sarcomas 52 radiation sensitizer 52 Omigard 52 resistant hormone refractory 52 Nexavar ® 52 intravenous methylnaltrexone 52 topical antifungal product 52 Taliglucerase alfa 52 Application BLA 52 HGS ETR2 52 telavancin NDA 52 chemosensitizer 52 lymphoma CTCL 52 calcineurin inhibitor 52 SPRYCEL ® 52 Ganite R 52 valopicitabine NM# 52 autologous cellular immunotherapy 52 COPEGUS 52 candidate DB# 52 gastrointestinal stromal tumor GIST 52 Fludara ® 52 liposomal formulation 52 BioGlue R 52 Locteron ® 52 transgenically produced product 52 EGFR TKI 52 carcinoma HCC 52 Biological License Application 52 Motesanib 52 brand ciclesonide HFA 52 nasal calcitonin product 52 Driv Driver 52 XYOTAX TM 52 Solazed 52 orally administered synthetic retinoid 52 Nasdaq PGNX today 52 palifosfamide administered intravenously 52 dirucotide 52 systemic ALCL 52 generation purine nucleoside 52 nalbuphine ER 52 irinotecan containing 52 oral methylnaltrexone 52 Zenvia ™ 52 CA9 SCAN 52 Zevalin R Ibritumomab 52 Phase IIIb clinical 52 Androxal TM 52 forodesine 52 phase IIb 52 PF # [002] 52 Xeloda ® 52 luteinizing hormone releasing 52 IL# PE#QQR 52 indolent follicular non 52 Sulonex TM 52 IgG1 monoclonal antibody 52 Peginterferon alfa 2b 52 aflibercept VEGF Trap 52 oral dihydropyrimidine dehydrogenase DPD 52 PNP inhibitor 52 oral talactoferrin 52 ACAPODENE TM 52 capecitabine Xeloda ® 52 treat chronic sinusitis 52 B CLL 52 metastatic pancreatic 52 Somatuline Depot 52 product ProBiora3 51 ocular formulation 51 Empatic TM 51 Zerenex 51 OPAXIO 51 trial evaluating PRX# 51 platinum refractory 51 Virulizin ® 51 IMPDH inhibitor 51 CDK cyclin dependent 51 IAP inhibitor 51 Kit CD# positive 51 gemcitabine chemotherapy 51 5 FU leucovorin 51 Archexin 51 docetaxel Taxotere ® 51 Cellegesic 51 CG# oncolytic virus 51 adecatumumab MT# 51 Phase III confirmatory 51 candidate deforolimus 51 Canvaxin 51 faropenem medoxomil 51 evaluating satraplatin 51 BiovaxID TM 51 OvaRex ® MAb 51 R roscovitine CDK cyclin 51 sBLA submission 51 dermatology biopharmaceutical 51 Proxinium TM 51 evaluating tivozanib 51 relapsed multiple myeloma 51 Tramiprosate ALZHEMED TM 51 vernakalant oral 51 HRPC ovarian cancer 51 SUTENT ® 51 worsening thrombocytopenia 51 castrate resistant prostate cancer 51 aflibercept 51 IMiDs R 51 overactive bladder AA# 51 Thiarabine 51 stage IIIb IV 51 metastatic colorectal 51 HCV NS5B polymerase 51 forodesine hydrochloride 51 evaluating bafetinib 51 FOLOTYN 51 RELISTOR ® 51 Veronate 51 candidate ridaforolimus 51 refractory gout 51 rusalatide acetate 51 post operative ileus 51 recombinant PSMA vaccine 51 adecatumumab 51 pegylated interferon peg IFN 51 MET inhibitor 51 telomerase inhibitor drug 51 selective androgen receptor modulator 51 R Saizen R 51 induced macular edema 51 CCR9 antagonist 51 BCG refractory carcinoma 51 TELCYTA 51 intravenous RSD# 51 phase III isavuconazole 51 Emergent marketed 51 Pruvel ™ prulifloxacin 51 MyVax R 51 Targretin capsules 51 UPLYSO 51 MKC# MT 51 Improved Progression 51 HATC follow 51 oral rivaroxaban 51 vernakalant iv 51 docetaxel chemotherapy 51 TAXUS Element Stent System 51 irinotecan doxorubicin oxaliplatin paclitaxel 51 telaprevir dosed 51 MAb therapy 51 Zenvia TM 51 Copegus 51 telomerase therapeutic 51 DASISION 51 sulfonylhydrazine class 51 RapidBlue TM 51 anthracycline containing 51 MIST II 51 sodium thiosulfate STS 51 selective estrogen receptor modulator 51 PROVENGE sipuleucel T 51 * olmesartan medoxomil 51 registrational 51 Randomized Phase II 51 personalized cellular immunotherapy 51 Hepatocellular Carcinoma HCC 51 NU# direct 51 QNEXA ® 51 MYDICAR ® 51 BLOOM DM 51 Inc. www.micromet inc.com 51 noninvasive outpatient 51 sorafenib tablets 51 sulfonylurea glimepiride 51 potent triglyceride lowering 51 anticancer compound 51 generation radiolabeled antibody 51 Crofelemer budesonide foam 51 Intravenous CP 51 investigational oral hepatitis C 51 RSD# iv 51 commercialize ZYFLO CR 51 Onco TCS 51 homez.#/telenews/www/wp-content/plugins/wp-postviSoufi 51 ATPace TM 51 vinca alkaloid 51 solanezumab 51 Azedra TM 51 hoFH 51 regorafenib 51 granted Ortec 51 AN# topical anti 51 Arimidex anastrozole 51 Auxilium anticipates 51 VALSTAR TM 51 confirmatory Phase III 51 selective inverse agonist 51 methylnaltrexone bromide 51 NPC 1C antibody 51 huC# DM4 51 TOCOSOL Paclitaxel 51 topical gel formulation 51 trastuzumab DM1 51 Altera Nebulizer System 51 Proellex TM 51 apaziquone 51 EFAPROXYN 51 acute peripheral arterial 51 Amoxicillin PULSYS Phase III 51 brentuximab vedotin SGN 51 miconazole MBT 51 clinical trials Archexin 51 antibiotic candidate Ramoplanin 51 EOquin TM 51 paclitaxel carboplatin 51 hormone LHRH antagonist 51 Matrix Phase 2b 51 Phase Ib II 51 DPX Survivac 51 gastrointestinal mucositis 51 talactoferrin 51 ridaforolimus 51 mCRC 51 ApoB SNALP 51 AVASTIN 51 oral isoform selective HDAC 51 Phase Ib study 51 FOLFOX6 51 generation nucleoside analog 51 tolevamer 51 Biologics License Application BLA 51 GATTEX TM 51 refractory NSCLC 51 pralatrexate injection folate analogue 51 GENASIS clinical 51 HYVISC R 51 investigational immunotherapy 51 Phase IIb III 51 IMPACT DCM clinical 51 product platforms AZX# 51 davalintide 51 AVN# Phase 51 RESTORE CLI trial 51 Sutent sunitinib malate 51 ORAL Sync 51 XL# XL# XL# XL# 51 Empatic 51 Dacogen injection 51 interferon beta 1a infertility 51 metastatic ocular 51 Nicotine Conjugate Vaccine 51 Azedra 51 ancrod 51 Annamycin 50 SILENOR TM 50 Civacir 50 monoclonal antibody IgG1 Mab 50 bile duct tumor 50 Hematide ™ peginesatide 50 Combination REOLYSIN R 50 BR.# 50 severe oral mucositis 50 ZOLINZA 50 Budesonide foam crofelemer 50 Nexavar sorafenib 50 dependent kinase inhibitor 50 proprietary HuCNS SC 50 motexafin gadolinium Injection 50 ™ pralatrexate injection 50 dextofisopam 50 compound INCB# 50 dyslipidemia hypertension diabetes 50 lupus renal disease 50 TRACON Pharmaceuticals Inc. 50 phase IIb III 50 Virulizin R 50 subcutaneous formulation 50 Vitrasert R 50 zileuton injection 50 intravenous belinostat 50 carcinoma mCRC 50 receiving chemoradiation therapy 50 oral ghrelin agonist 50 Boxed Warnings 50 PEG SN# 50 unresectable Stage III 50 INTEGRILIN ® 50 BEMA TM LA 50 PRIMO CABG 50 ZEVALIN ® 50 PEG interferon 50 FOLFIRI chemotherapy 50 S OMX GEN 50 intravesical infusion therapy 50 pipeline ImmunoGen collaborators 50 markets HP Acthar 50 pentadentate logo R 50 coronary stent merged 50 lumiliximab 50 PLK1 SNALP 50 generation PNP inhibitor 50 WX UK1 50 S1P antibody 50 L MTP PE 50 non constipating irritable 50 Cand5 50 LEP ETU 50 MEK Inhibitor 50 oxymorphone ER 50 Soliris TM eculizumab 50 NEBIDO VANTAS SUPPRELIN LA 50 taxane chemotherapy administered 50 monoclonal antibody conjugated 50 aleglitazar 50 bazedoxifene 50 Ganite ® 50 LE SN# 50 R alglucosidase alfa 50 Elagolix 50 novel synthetic peptide 50 oritavancin semi 50 biologic antibody 50 lenalidomide Revlimid R 50 resectable pancreatic cancer 50 SPARLON 50 olmesartan medoxomil 50 candidate oral AP# 50 IMA# 50 Genasense oblimersen sodium Injection 50 confirmatory clinical 50 endoscopic autofluorescence imaging 50 therapy Tovaxin 50 PrevOnco 50 PRT# 50 CYT# potent vascular disrupting 50 custirsen 50 drug pipeline TAFA# 50 pan histone deacetylase 50 oxybutynin ATD ™ 50 ® bortezomib 50 detectors diodes directional 50 signal detection CTSD 50 FOLFOX regimen 50 targeted radiotherapeutic 50 TOCOSOL R 50 individualized cellular immunotherapy 50 Ceflatonin ® 50 ENABLE Phase 2 50 BENLYSTA belimumab 50 INTERCEPT red 50 Asentar TM 50 registrational trial 50 trastuzumab Herceptin R 50 gastrointestinal stromal 50 antihypertensive therapies 50 Antigen Express website 50 Provectus Pharmaceuticals specializes 50 www.allos.com 50 Clolar ® 50 BRILINTA 50 KRAS wild 50 metastatic HER2 negative 50 oral deforolimus 50 dasatinib Sprycel 50 Ovitrelle R Serostim 50 compound ITMN 50 Tarceva TM 50 Canvaxin TM 50 Achieves Primary Endpoint 50 non squamous NSCLC 50 cytogenetic response rates 50 systemically administered 50 recurrent NSCLC 50 Celacade TM technology 50 e mail lifestyle@readingeagle.com 50 MEND CABG II 50 selective angiogenic kinase inhibitor 50 RSD# IV 50 squamous non 50 non nucleoside inhibitor 50 Frova ® 50 ALN PCS 50 small molecule Hedgehog 50 5 lipoxygenase inhibitor 50 phenylalanine ammonia lyase 50 Augment Injectable 50 Stage IIIB IV 50 metformin sulfonylurea 50 glycoprotein IIb IIIa inhibitor 50 inhaled formulation 50 Act PDUFA date 50 mocetinostat MGCD# 50 IMiDs ® 50 novel antimitotic agent 50 Vidaza ® 50 HeartMate ® 50 vidofludimus 50 omecamtiv mecarbil formerly 50 Inc. NASDAQ ONTY 50 novel antifolate currently 50 metastatic carcinoid 50 bardoxolone 50 picoplatin 50 Serostim ® 50 GW# [003] 50 Alzhemed TM 50 AERx ® 50 ABILIFY Injection 50 Belimumab 50 Fodosine 50 NicVAX TM 50 Seliciclib 50 Omigard TM 50 essential thrombocythemia ET 50 LEVADEX ™ 50 plus dexamethasone 50 candidates Azedra TM 50 polysaccharide polymer 50 developing ACAPODENE 50 advanced metastatic renal 50 Phase 1b clinical 50 occlusion PAO 50 Panzem NCD 50 untreated metastatic colorectal 50 naïve HCV 50 supplemental biologics 50 fully bioabsorbable 50 INTEGRILIN 50 Corlux 50 PresbyLens ® 50 CLARITY study 50 metastatic androgen independent 50 additionally contraindicated 50 ACTEMRA TM 50 Fovea Pharmaceuticals subsidiary 50 aldehyde dehydrogenase ALDH2 deficiency 50 Provenge sipuleucel T 50 lesinurad 50 Aflibercept 50 rilonacept Injection 50 ZADAXIN ® 50 SANVAR 50 XP# XP# 50 oral proteasome inhibitor 50 constipation OIC 50 methylnaltrexone 50 metabolic disorders Saizen R 50 LEUKINE 50 human IgG1 monoclonal 50 application sNDA 50 refractory peripheral T 50 Oracea TM 50 Phase #/#a trial 50 registrational Phase 50 doxorubicin Transdrug ® 50 advanced carcinoid 50 httpdocs wp includes rss.php 50 Dabigatran etexilate 50 cetuximab Erbitux R 50 oxidative stress inducer 50 label Lipofen R 50 influenza BCX# purine nucleoside 50 im peramivir 50 VANTAS ® 50 tesetaxel 50 Optiquel ™ 50 Onalta ™ 50 MKC# 50 GVAX vaccine 50 NASDAQ CYTK announced 50 OncoVEX 50 ® bevacizumab 50 candidate epratuzumab 50 cytomegalovirus immune globulin 50 Vernakalant 50 novel synthetic PEGylated 50 Powerlink ® 50 CCX# 50 Tumour Vascular Disrupting Agent 50 metastatic SCCHN 50 EGFr expressing metastatic colorectal 50 synthetic lipoglycopeptide antibiotic 50 INCB# [001] 50 Xcellerated T Cells 50 vaccines oncolytic virus 50 anti VEGF aptamer 50 http:/www.pharmion.com 50 Pegloticase 49 Neurodex TM 49 oxypurinol 49 successfully commercialize Iluvien 49 Acetavance TM intravenous acetaminophen 49 #-INFO-SKX 49 ILUVIEN ® 49 GALNS N acetylgalactosamine 49 drugs FUSILEV 49 platforms GVAX 49 Phase 2a clinical 49 Nasdaq NPSP announced 49 Firdapse TM amifampridine phosphate 49 Initiate Phase 49 infusional 5-FU/LV 49 azelastine hydrochloride 49 eSensor detection technology 49 Sular formulation 49 Initiates Phase II 49 http:/www.sunesis.com 49 HGS# 49 proprietary transdermal patch 49 trastuzumab emtansine T DM1 49 GRNVAC1 49 Emtriva Viread 49 initiate multicenter 49 TNFerade ™ 49 ALTROPANE R 49 deforolimus 49 telaprevir VX 49 erlotinib Tarceva ® 49 comparing XIENCE V 49 goserelin 49 AQ4N 49 investigating pralatrexate 49 AEG# 49 Maximum Tolerated Dose MTD 49 P#X# antagonist 49 oncolytic virus therapies 49 low dose cytarabine 49 oral prodrug 49 CCR5 inhibitors entry 49 TTF Therapy 49 ALVESCO ® 49 neovascular age 49 Exelixis compounds 49 EMPOWER Study 49 relapsed leukemia 49 HuMax TAC 49 Accelr8 licenses 49 Pirfenidone 49 #/#/# Cytokinetics Incorporated 49 non splenectomized 49 somatropin Kuvan R 49 Emezine 49 dihydrochloride Phase 3 49 DU #b 49 Amigal TM 49 selective A2A adenosine receptor 49 sodium Injection 49 TKM ApoB 49 valtorcitabine 49 Insegia 49 HER2 positive metastatic breast 49 developing adecatumumab 49 pivotal Phase III 49 gemcitabine cisplatin 49 4SC AG ISIN DE# 49 hyaluronidase enzyme 49 Dycom Announces 49 ZEVALIN 49 ADVEXIN therapy 49 atrial fibrillation budiodarone ATI 49 elacytarabine 49 dirucotide MBP# 49 Phase #b/#a trial 49 TRISENOX ® 49 exploratory Phase IIa 49 CTA# Injection 49 TLR9 agonist IMO 49 Dementia Related Psychosis 49 anti EGFR antibody 49 headache nasopharyngitis 49 EVIZON TM squalamine lactate 49 mycophenolic acid 49 paclitaxel poliglumex 49 herpetic keratitis 49 BLA submission 49 candidate EFAPROXYN TM 49 refractory AML 49 cutaneous T 49 Temodar ® 49 Dapagliflozin 49 angiotensin II receptor blocker 49 class anticancer quinolone 49 tesmilifene 49 Urocidin TM 49 Inc. OTCBB BVTI 49 refractory acute myeloid 49 taxane chemotherapy 49 HepeX B TM 49 Ophena TM 49 kidney urologic 49 ofatumumab 49 home httpd vhosts 49 drug figitumumab 49 Zemiva ™ 49 chemotherapy cisplatin 49 Gonal f R follitropin 49 gemcitabine Gemzar 49 inadequate glycemic 49 BrachySil 49 TRACON Pharmaceuticals 49 Microplasmin 49 IIa clinical trial 49 Study GL# 49 QuadraSphere 49 orally inhaled migraine 49 zalutumumab 49 solid tumors ZYBRESTAT 49 OMS# 49 paclitaxel Taxol ® 49 investigational monoclonal antibody 49 Oncophage vitespen 49 Adjuvant Treatment 49 Investigational Device Exemption 49 Cintredekin Besudotox 49 previously untreated follicular 49 epothilone KOS 49 SWX BSLN 49 http:/www.nxstage.com 49 ASONEP ™ 49 MyVax ® 49 palifosfamide 49 cancer indications bafetinib 49 small molecule chemotherapeutic 49 relapsed MCL 49 Dendreon investigational 49 SAR# [004] 49 Tocosol Paclitaxel 49 CORLUX CORT # 49 TLK# 49 folinic acid FA 49 Phase Ib 49 steroid refractory ulcerative 49 mitogen activated ERK kinase 49 neuropathy sparing 49 Brentuximab Vedotin SGN 49 apoptosis proteins 49 BRAF inhibitor 49 Hexvix ® 49 drug conjugate 49 Initiated Phase 49 TURNING INSIGHTS INTO HOPE 49 SILENOR 49 albiglutide 49 AMD# [002] 49 NASDAQ OSIR 49 obatoclax 49 Vidaza R 49 PRECISE trial 49 histamine dihydrochloride 49 LidoPAIN SP 49 PolyHeme ® 49 triggers apoptosis programmed 49 Vicriviroc 49 UVIDEM 49 neoprobe ® GDS 49 AdhTAP 49 BiTE antibody 49 EGFR HER2 49 AzaSite Plus 49 signal transduction inhibitor 49 TSX QLT QLT 49 brain metastases originating 49 investigational humanized monoclonal antibody 49 IMiDs ® compound 49 developing ostarine selective 49 Femring ® 49 PEGylated Fab fragment 49 Nasdaq UNIS 49 Second Pivotal Phase 49 TransVax 49 Phase Ib clinical trials 49 ARIKACE ™ 49 Somatuline R Depot 49 EDEMA3 trial 49 Lamictal ODT 49 Silenor ® doxepin 49 relapsed Hodgkin lymphoma 49 OvaRex R 49 Neuromodulation System 49 Acute Myeloid Leukemia AML 49 MelaFind ® 49 cetuximab Erbitux ® 49 Novantrone 49 Specifid 49 relapsing remitting MS RRMS 49 YONDELIS 49 sulfonylurea metformin 49 Allovectin 7 ® 49 novel tubulin binding 49 CIMZIA r certolizumab pegol 49 candidate CRLX# 49 Gonal f R 49 Trastuzumab DM1 49 receptor tyrosine kinase inhibitor 49 Staphylococcus aureus Polysaccharide Conjugate 49 sodium glucose cotransporter 49 morphometric vertebral fractures 49 CLIRS trial 49 ReN# stem cell 49 Visit Cognex 49 Tekamlo 49 dexanabinol 49 CCR5 mAb 49 Sudhir Agrawal D.Phil 49 inhaled prostacyclin 49 Rebif R 49 biliary tract cancer 49 Orathecin 49 vapreotide acetate 49 small molecule glucokinase 49 novel nucleoside analog 49 NEBIDO R 49 novel therapeutic antibodies 49 tumor activated prodrug 49 PLX# RG# 49 ASONEP TM 49 saline placebo 49 mCRC patients 49 phase IIa clinical 49 pseudobulbar affect PBA 49 particularly SANCTURA XR 49 vascular disrupting agent 49 Market Authorization Application 49 MAXY alpha 49 Edwards SAPIEN valve 49 SPEAR Study 49 TRC# 49 JOULFERON 49 stage IIIB 49 Capesaris 49 MEK inhibitor RDEA# 49 EmbraceAC 49 ViaDerm hPTH #-# 49 combining voreloxin 49 Surgical resection 49 AVOREN 49 5 HT3 antagonist 49 SUPPRELIN R LA 49 liver resection surgeries 49 Submits Biologics License Application 49 DepoBupivacaine TM 49 FUSILEV ® 49 NEBIDO 49 pertuzumab 49 pharmacokinetic equivalence 49 developed preclinically 49 www.incyte.com 49 IMPACT DCM 49 efaproxiral 49 Solorel TM 49 BLP# Liposome Vaccine 49 Azixa 49 Tibotec Therapeutics division 49 apricitabine ATC 49 Diamyd R 49 Actemra tocilizumab 49 abacavir lamivudine 49 Zoraxel 49 EOquin 49 panitumumab Vectibix R 49 ritonavir boosted protease inhibitor 49 acetonide FA 49 www.biomimetics.com 49 recurrent malignant glioma 49 CIMZIA TM 49 volociximab 49 candidate Zemiva TM